2703, 2018

Caelum Biosciences Announces Updated Phase 1b Data Presented at 16th International Symposium on Amyloidosis

View PDF New data analysis demonstrates correlation between sustained decrease in NT-proBNP and improvement in global longitudinal strain in cardiac population following CAEL-101 treatment NEW YORK, NY – March 27, 2018 – Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ: FBIO) Company developing treatments for rare and life-threatening diseases, today announced a new analysis of data from the Phase 1b trial of CAEL-101 (mAb 11-1F4) for the treatment of

2103, 2018

Caelum Biosciences Announces Clinical Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 16th International Symposium on Amyloidosis

View Press Release (PDF) Final analysis of data from Phase 1a/1b trial and additional global longitudinal strain response to be presented NEW YORK, NY – March 21, 2018 – Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ: FBIO) Company developing treatments for rare and life-threatening diseases, today announced that the final analysis of data and additional global longitudinal strain response from the Phase 1a/1b trial of Caelum’s CAEL-101 (mAb

1112, 2017

Caelum Biosciences Announces Positive Phase 1a/1b Data Demonstrating CAEL-101 (mAb 11-1F4) Improves Organ Function in AL Amyloidosis

View Press Release (PDF) Eight of 12 patients (67 percent) with cardiac involvement responded to therapy with a median time to cardiac response of 21 days 14 of 24 (63 percent) of patients demonstrated organ response CAEL-101 dosed once weekly was found to be well tolerated with no dose-limiting toxicity Data presented by Columbia in oral session at ASH Annual Meeting to support advancement into Phase 2b/3 trial NEW YORK,

0111, 2017

Caelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting

View Press Release (PDF) Research partner Columbia University to present full analysis of Phase 1a/1b data NEW YORK, NY – November 1, 2017 – Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ: FBIO) Company focused on developing treatments for rare and life-threatening diseases, today announced that Phase 1a/1b data on CAEL-101 for the treatment of relapsed or refractory amyloid light chain “AL” amyloidosis has been selected for an oral

1707, 2017

Fortress Biotech Announces Filing of Provisional Application for Caelum Biosciences’ CAEL-101

View Press Release (PDF) Patent application filed by Columbia University for novel antibody licensed to Caelum NEW YORK, NY – July 17, 2017 – Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that Columbia University (“Columbia”) has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) pertaining to CAEL-101, which was licensed

0106, 2017

Fortress Biotech Subsidiary Caelum Biosciences Enters Biopharmaceutical Manufacturing Agreement with Patheon

View Press Release (PDF) Agreement will support Phase 2/3 studies of Caelum’s CAEL-101 in AL amyloidosis NEW YORK, NY – June 1, 2017 – Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that its subsidiary Caelum Biosciences (“Caelum”) has entered a biopharmaceutical manufacturing agreement with Patheon N.V. for process development and current good manufacturing practices (cGMP)

0405, 2017

Fortress Biotech Announces Final Patient Dosed in Phase 1B Trial of CAEL-101 for the Treatment of AL Amyloidosis

View Press Release (PDF) CAEL-101 is in development by Fortress subsidiary Caelum Biosciences Preliminary Phase 1b data expected mid-2017; full data readout anticipated in late 2017 Phase 2 study planned for the first half of 2018 NEW YORK, NY – May 4, 2017 – Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that study sponsor Columbia

0504, 2017

Fortress Biotech Announces Orphan Drug Designations for CAEL-101 in Amyloidosis

View Press Release (PDF) FDA acknowledges transfer to Caelum Biosciences, a Fortress Biotech Company New York, NY – April 5, 2017 – Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that the U.S. Department of Health & Human Services has confirmed the transfer of two U.S. Food and Drug Administration (FDA) Orphan Drug Designations for CAEL-101

0401, 2017

Fortress Biotech forms a new subsidiary, Caelum Biosciences, Inc., to develop a novel treatment for AL Amyloidosis

Download the Press Release (PDF) Caelum Program Evaluating CAEL‐101 (11‐1F4) for AL Amyloidosis In‐licensed from Columbia University Data from ongoing Phase 1a/1b study of CAEL‐101 presented by Dr. Suzanne Lentzsch at ASH have demonstrated CAEL‐101 is safe and well tolerated; 67 percent of patients showed improvement in organ function. Michael Spector to Serve as Chief Executive Officer NEW YORK, NY – January 4, 2017 – Fortress Biotech, Inc. (Nasdaq: FBIO)